SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001824293-22-000027
Filing Date
2022-04-27
Accepted
2022-04-27 16:05:25
Documents
5
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2022proxystatement.htm DEF 14A 513074
2 GRAPHIC dbaker.jpg GRAPHIC 2612
3 GRAPHIC logo_filings.jpg GRAPHIC 47751
4 GRAPHIC vallon_prxyxp73143x2263343.jpg GRAPHIC 507174
5 GRAPHIC vallon_prxyxp73143x2263343a.jpg GRAPHIC 161796
  Complete submission text file 0001824293-22-000027.txt   1504546
Mailing Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103
Business Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103 (267) 207-3606
Vallon Pharmaceuticals, Inc. (Filer) CIK: 0001824293 (see all company filings)

IRS No.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40034 | Film No.: 22859498
SIC: 2834 Pharmaceutical Preparations